Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 9B (TBC1D9B) is a large (~140 kDa) protein with two N-terminal GRAM domains, a central TBC domain, and a C-terminal EF hand motif[1]. It functions primarily as a GTPase-activating protein for Rab11a, modulating its activity to regulate membrane trafficking—specifically the transcytosis of immunoglobulin A (IgA) in polarized epithelial cells[1][2]. TBC1D9B is also implicated in autophagic flux regulation, interacting with LC3B on autophagosome membranes and potentially ensuring proper autophagosome trafficking and degradation[3]. Although it can interact with additional Rabs (Rab11b, Rab4a, and under certain magnesium conditions, Rab8a), its GAP activity is most pronounced for Rab11a[1][2]. TBC1D9B is not currently considered a direct therapeutic target, nor are there drugs or biomarker applications described in the literature or clinical practice[5][6]. Its biological relevance stems from regulation of protein trafficking and autophagy, and dysfunction may theoretically contribute to cellular transport disorders, but direct disease links have not been established[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 9B (TBC1D9B).